FDA staff says new oral MS drug Lemtrada may be too risky

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

FDA staff says new oral MS drug Lemtrada may be too risky

Postby MSUK » Fri Nov 08, 2013 9:26 am

Sanofi’s multiple sclerosis treatment Lemtrada may not offer enough benefit to patients to outweigh risks including cancer, U.S. regulators said. The French drugmaker’s shares fell.

Lemtrada’s “serious and potentially fatal safety issues,” which include the risk of autoimmune and thyroid diseases, may make the medicine too dangerous to approve unless there is substantial clinical benefit shown, Food and Drug Administration staff said in a report today. Agency reviewers also questioned whether Sanofi conducted adequate trials to prove the annual infusion works.

“That’s like a death sentence,” said Fabian Wenner, an analyst with Kepler Cheuvreux in Zurich, “It isn’t what everyone expected, an issue with the safety. It seems to be a more fundamental issue here.” - Read More- http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2483
Joined: Wed Oct 14, 2009 3:00 pm


Re: FDA staff says new oral MS drug Lemtrada may be too risk

Postby SarahLonglands » Fri Nov 15, 2013 11:04 am

This original posting about Lemtrada seems more accurate than the new one you posted yesterday...............Sarah
An Itinerary in Light and Shadow Completed Dr Charles Stratton / Dr David Wheldon abx regime for aggressive secondary progressive MS in June 2007, after four years. Still improving with no relapses since starting. Can't run but can paint all day.
Family Elder
Posts: 2143
Joined: Thu Jun 17, 2004 3:00 pm
Location: Bedfordshire UK

Return to Campath (Lemtrada, Alemtuzumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service